Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients

No Thumbnail Available
Authors
Simeng, Lin
Nicholas, A. Kennedy
Aamir, Saifuddin
Diana Muñoz, Sandoval
Catherine, Reynolds
Rocio Castro, Seoane
Sherine, Kottoor
Franziska, Pieper
Kai-Min, Lin
David, K. Butler
Journal
Research Square
Type
Journal Article
Publisher
Unknown
Rights
© Research Square 2021
To inform healthcare policy for immunosuppressed patients there is a need to define SARS-CoV-2 vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell responses in patients treated with anti-tumour necrosis factor (anti-TNF), a commonly used biologic in inflammatory diseases, compared to patients treated with vedolizumab, a gut-specific antibody targeting integrin a4b7 that does not impair systemic immunity. In anti-TNF recipients, the magnitude of anti-SARS-CoV2 antibodies was reduced five-fold, and rapidly decayed towards the seroconversion threshold by 14 weeks after second dose of vaccine. In contrast, anti-SARS-CoV-2 antibodies were sustained up to 16 weeks in vedolizumab-treated patients. Anti-SARS-CoV2 antibody decay was not observed in vaccinated patients previously infected with SARS-CoV-2. T cell responses were absent in one-fifth of anti-TNF and vedolizumab-treated patients after a second dose of either vaccine. Our data have important implications for anti-TNF recipients, including the need for vaccine prioritization, booster doses, and social distancing strategies.
Citation
Note
Not held